Strategic acquisitions of high-quality outpatient properties and diversified hospital-affiliated tenants align with demographic healthcare trends, supporting long-term revenue and asset growth. Higher refinancing costs and tenant consolidation risk threaten profitability and rental income stability amid a challenging interest rate and healthcare landscape, while legacy medical office assets face rising vacancies and CapEx demands.
Cyborg Score Rationale
The company provided earnings per share guidance of 4.300-4.450 for FY 2026, compared to the consensus earnings per share estimate of 1.740. The stock trades at a price-to-earnings ratio of -143.84 with a beta of 1.18. Mixed signals from analyst ratings and valuation pressures offset strong dividend yield.
Top Insights
The company is rebranding to Chiron Real Estate Inc., effective February 23, 2026, and will trade under ticker XRN.
Dividend yield of 8.3% on annualized basis of $3.00 per share.
Consensus analyst rating is "Moderate Buy" with average target price of $42.00.
GMRE underperformed the US Health Care REITs industry which returned 27.8% over the past year.
Named Competitors
Outpatient Medical Properties — Leading healthcare REIT with medical office focus
Healthcare Properties — Diversified healthcare REIT with strong market presence
Healthcare REIT — Senior housing and healthcare properties REIT
Care-Related Properties — Senior housing and skilled nursing facility REIT
Recent Developments
(Feb 2026) Company announced rebrand to Chiron Real Estate Inc., trading under new ticker XRN effective February 23, 2026.
(Feb 2026) Updated FY 2026 earnings guidance to $4.300-4.450 EPS compared to consensus estimate of $1.740.
(Jan 2026) Weiss Ratings upgraded shares from "sell" rating to "hold" rating.
(Sep 2025) One-for-five reverse stock split effective September 19, 2025.
Open the full interactive Global Medical REIT Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.